OPCH

Rating neutralAI Memo

Option Care Health

As of 2026-05-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q1 growth reset and lowered 2026 revenue outlook • 2026-08-04

Base target: $24 / p=50% prob

Biggest risk

The bear view is that chronic inflammatory disease attrition and mix pressure are not transient enough, revenue guidance was cut, gross profit is under pressure, and a growth-function leadership change adds execution risk at the wrong time.

Invalidation

Break below $17 or thesis failure.

What would change my mind?

The constructive view is that OPCH still has national scale, acute therapy growth, maintained 2026 adjusted EPS/EBITDA guidance, and added liquidity via an $850M revolver, so the post-earnings selloff may have over-discounted a therapy-mix issue rather than a full-franchise impairment.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-06

Base target

$24

p=50%

Bull target

$30

p=25%

Bear target

$17

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Chief Growth Officer departure raises execution sensitivity
Earnings resilience and liquidity partially offset top-line pressure
The constructive view is that OPCH still has national scale, acute therapy growth, maintained 2026 adjusted EPS/EBITDA guidance, and added liquidity via an $850M revolver, so the post-earnings selloff may have over-discounted a therapy-mix issue rather than a full-franchise impairment.

BearKey bullets

Chief Growth Officer Christopher L.
Grashoff is departing effective May 8, 2026, increasing scrutiny on commercial execution during a growth slowdown.
[#8-K-2026-05-05]

WatchKey bullets

Q1 growth reset and lowered 2026 revenue outlook

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $24 (p=50%)

Target spread vs base: +25% / -29%

Scenario probabilities

Bull Target: $30 (p=25%)Base Target: $24 (p=50%)Bear Target: $17 (p=25%)

Commentary

Primary-source evidence points to a cautious rather than broken thesis: Q1 exposed a real revenue-growth problem, and recent headlines were negative, including a selloff framed around disappointing growth. The $21.30 anchor implies the market has already repriced materially lower after the April 30 update, but fresh analyst revision coverage in the packet is limited, so confidence should stay moderate-low until a post-cut estimate reset and another operating datapoint arrive.

As of 2026-05-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Chief Growth Officer departure raises execution sensitivity
Earnings resilience and liquidity partially offset top-line pressure

Scenarios

Bull Target (Scenario probability)

$30 / p=25% prob

Base Target (Scenario probability)

$24 / p=50% prob

Bear Target (Scenario probability)

$17 / p=25% prob

Analysis 2026-05-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-04
Q1 growth reset and lowered 2026 revenue outlook
Q1 net revenue rose 1.3% to $1.351B, but gross profit fell 0.4% and management said chronic inflammatory disease dynamics, patient attrition, and unfavorable therapy mix should reduce 2026 gross profit by about $55M; full-year revenue guidance was reset to $5.675B-$5.775B. The next debate is whether acute growth and corrective actions can offset chronic mix pressure. [#10-Q-2026-04-30]
Prob 70.00% • Move 9.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Chief Growth Officer departure raises execution sensitivity
2026-05-08
The company disclosed that Chief Growth Officer Christopher L. Grashoff will depart effective May 8, 2026, immediately after a quarter where management said it was not satisfied with revenue growth momentum. That does not change the franchise by itself, but it raises near-term scrutiny on commercial execution and referral growth. [#8-K-2026-05-05]
Prob 65% • Move -6% • Priced-in 60%

Long-term Catalysts

Months to a year

Earnings resilience and liquidity partially offset top-line pressure
2026-12-31
Despite the revenue reset, management maintained full-year adjusted EPS guidance of $1.82-$1.92 and adjusted EBITDA guidance of $480M-$505M, while the revolver was expanded to $850M and the board-authorized repurchase capacity remains large. That supports downside cushioning if execution stabilizes. [#10-Q-2026-04-30]
Prob 60% • Move 12% • Priced-in 45%

Risks

Chief Growth Officer Christopher L. Grashoff is departing effective May 8, 2026, increasing scrutiny on commercial execution during a growth slowdown. [#8-K-2026-05-05]
Management said CID portfolio dynamics, patient attrition, and unfavorable therapy mix are expected to reduce 2026 gross profit by about $55 million. [#10-Q-2026-04-30]
Revenue concentration remains notable: the largest payer represented about 14% of Q1 2026 revenue. [#10-Q-2026-04-30]
Supply concentration remains meaningful, with about 67% of pharmaceutical and medical supply purchases coming from four vendors. [#10-Q-2026-04-30]

Peers

Symbol	Summary
MMSI	Merit Medical is closer on market cap than on business model; it is a medical device company, so any multiple read-through to OPCH's home infusion services model is limited.
RDNT	RadNet is another closer-cap healthcare-services name, but outpatient imaging economics differ materially from home infusion, so peer support is loose rather than thesis-forming.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-06

Loading AI feed…

Symbol

Summary

MMSI

Merit Medical is closer on market cap than on business model; it is a medical device company, so any multiple read-through to OPCH's home infusion services model is limited.

RDNT

RadNet is another closer-cap healthcare-services name, but outpatient imaging economics differ materially from home infusion, so peer support is loose rather than thesis-forming.